Alnylam Pharmaceuticals
Clinical trials sponsored by Alnylam Pharmaceuticals, explained in plain language.
-
Heart protein disease drug tested for Long-Term safety in 700 patients
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effectiveness of a drug called vutrisiran in people with a heart condition caused by abnormal protein buildup (ATTR amyloidosis with cardiomyopathy). About 700 adults who were already in related studies will continue or switch to vutri…
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 13:57 UTC
-
New shot every 3 months shows promise for rare heart disease
Disease control OngoingThis study tests a drug called vutrisiran in 655 adults with a rare disease that causes heart failure. The drug aims to reduce deaths and heart-related hospital visits. Participants receive an injection every 3 months and are followed for several years.
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Researchers track rare kidney disease to see how treatment holds up in real life
Knowledge-focused OngoingThis study follows 207 people with primary hyperoxaluria type 1 (PH1), a rare genetic condition that causes kidney stones and kidney damage. Researchers are watching how the disease naturally progresses and checking the long-term safety and effectiveness of the drug lumasiran in …
Sponsor: Alnylam Pharmaceuticals • Aim: Knowledge-focused
Last updated May 08, 2026 12:01 UTC